NSAID Selection and Management for Inflammatory Conditions

Initial NSAID Selection and Dosing

The American College of Rheumatology recommends starting with ibuprofen 1.2 g daily as first-line NSAID therapy after acetaminophen fails to provide adequate symptom relief for degenerative spinal arthritis and inflammatory conditions 1
Ibuprofen is designated as the lowest risk NSAID for serious gastrointestinal complications compared to all other NSAIDs across 12 controlled epidemiological studies 1
At low analgesic doses (<1200 mg/day), ibuprofen maintains favorable GI safety due to its high analgesic-to-anti-inflammatory ratio 2
At anti-inflammatory doses (≥2400 mg/day), ibuprofen's safety advantage completely disappears, and GI bleeding risk becomes equal to other non-selective NSAIDs including naproxen 1, 2

The GI risk stratification for NSAIDs is: ibuprofen ≤1.2 g daily has the lowest risk, diclofenac, naproxen, and high-dose ibuprofen (2.4 g) have intermediate risk, and azapropazone has the highest risk 1
For patients with GI risk factors requiring any NSAID, gastroprotection with proton pump inhibitors (PPIs) or misoprostol is mandatory, regardless of which NSAID is chosen 1, 2, 3
Misoprostol reduces serious upper GI complications with a number needed to treat (NNT) of 264 over 6 months 1
PPIs are equally effective as misoprostol for preventing NSAID-induced ulcers and are better tolerated 1

For older adults (>60 years), NSAIDs should be used "rarely and with extreme caution" only after safer therapies have failed, and require mandatory gastroprotection with PPI or misoprostol 3
In pregnancy, early exposure to NSAIDs shows no evidence of increased miscarriage or teratogenicity, with most reassuring data for ibuprofen, but all NSAIDs should be discontinued after gestational week 28 3

Baseline and every 3 months, monitoring should include blood pressure 4, liver function studies 3, and CBC and fecal occult blood 3
NSAIDs should be used as first-line drug treatment for patients suffering from pain and stiffness, up to the maximum dose, taking risks and benefits into account 4, 5
Evidence from axial spondyloarthritis studies demonstrates no significant efficacy differences between NSAIDs, including ibuprofen, diclofenac, and naproxen 1